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Abstract 
Nowadays cancer represents a prominent challenge in clinics. Main achievements in cancer 
management would be the development of highly accurate and specific diagnostic tools for early 
detection of cancer onset, and the generation of smart drug delivery systems for targeted chemotherapy 
release in cancer cells. In this context, protein-based nanocages hold a tremendous potential as devices 
for theranostics purposes. In particular, ferritin has emerged as an excellent and promising protein-
based nanocage thanks to its unique architecture, surface properties and high biocompatibility. By 
exploiting natural recognition of the Transferrin Receptor 1, which is overexpressed on tumor cells, 
ferritin nanocages may ensure a proper drug delivery and release. Moreover, researchers have applied 
surface functionalities on ferritin cages for further providing active tumor targeting. Encapsulation 
strategies of non metal-containing drugs within ferritin cages have been explored and successfully 
performed with encouraging results. Various preclinical studies have demonstrated that 
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nanoformulation within ferritin nanocages significantly improved targeted therapy and accurate 
imaging of cancer cells. Aims of this review are to describe structure and functions of ferritin 
nanocages, and to provide an overview about the nanotechnological approaches implemented for 
applying them to cancer diagnosis and treatment.  
1. Introduction 
Cancer is a leading cause of death worldwide, accounting for 8.2 million deaths in 2012 [1]. A main 
goal of current cancer research is early recognition of cancer cells and selective treatment, before the 
cancer can progress to an unfavourable stage. Based on this rationale, the aim of several modern 
therapeutic approaches for cancer is to selectively remove the tumor before it evolves into its superior 
stages, and the eventual onset of metastases. For this scenario to be successful there is a growing need to 
develop: 1) novel and more sensitive diagnostic tools to improve screening accuracy and the detection 
rate of malignancies, staging and follow up settings, and to achieve less extensive surgery or medical 
therapy; 2) new drug formulations with enhanced efficacy toward cancer cells and reduced toxicity 
toward healthy cells [2].  
Nanotechnology holds great clinical potential in reaching these major goals and a number of 
nanodevices have been designed to specifically target cancer cells. These nanodevices can be loaded 
with different kinds of chemotherapeutics and/or contrast agents, and provide unmatched promise for 
development of theranostic devices for both cancer diagnosis and treatment. Indeed, nanoparticles have 
demonstrated their potential to solve crucial issues involving bioavailability, tissue penetration and 
circulation time [3]. Several nanoparticles constructed from metals, semi-conductors or polymers, have 
been tested in preclinical studies [4], but only a few of them have been clinically approved due to their 
toxicity, immunogenicity and sequestration by the reticulo-endothelial system [5]. Therefore, much 
effort has been directed into the design and synthesis of chemically engineered nanostructures that are 
biologically compatible.  
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Naturally occurring nanoparticles have existed for millions of years, and they include a wide variety of 
nanostructures, which may be formed by inorganic (i.e. magnetosomes) or organic materials. These 
nanoparticles can be intracellular or extracellular and may have different biological roles [6]. Despite 
these differences, natural nanoparticles are charming from the biomedical point of view due to their 
uniform structure, low toxicity, and ability to evade the immune system. Moreover, they are easily 
degraded after fulfilling their function [6,7]. These features place them ahead of inorganic or synthetic 
materials in clinical translation [7]. Biological nanoparticles are assembled from molecules or atoms 
synthesized in a biological system with sizes ranging from 1 to 100 nm. They include magnetosomes, 
lipoproteins, viruses, exosomes and ferritins [6].  
Magnetosomes are specialized organelles with narrow size (50-70 nm in diameter), uniform morphology 
and low toxicity; they have evolved from magnetotactic bacteria and are composed of a lipid bilayer 
surrounding magnetic iron-containing minerals [8-10]. Lipoproteins are self-assembling structures that 
contain phospholipids, non-esterified cholesterol and specialized proteins, forming a spherical or 
discoidal shell (from 7 to >80 nm), which surrounds a core of non-polar lipids, triacylglycerols and 
esterified cholesterols [11, 12]. Exosomes are nanometer-sized structures secreted by cells and consist of 
an external lipid bilayer, which offers a non-immunogenic and non-toxic mechanism for the delivery of 
targeted proteins or nucleic acids, protecting them from degradation and macrophage endocytosis [13-
16]. Viruses and virus-like particles may also be considered to be biological nanoparticles. They include 
a wide variety of sizes and morphologies with defined geometries, uniform shape and a robust protein 
shell. They are suitable for chemical- and bio-conjugation. Although their capsids are stable over a wide 
range of pH and temperatures, they are difficult to produce in bulk, and this represents a severe 
limitation for their use in nanotechnology [17].  
Among all classes of biological nanoparticles here we focus on ferritins, which are iron storage and 
transport proteins found in most living organisms [18]. Recombinant ferritin provides a central cavity, 
which can be efficiently loaded with transition metals, drugs, fluorescent molecules or contrast agents 
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[19, 20]. Since it has a uniform cage, ferritin allows the precise control of the amount of encapsulated 
molecules, which is a critical feature in defining drug dosage. Moreover, the protein shell of ferritins can 
be easily modified either chemically or genetically to introduce different functionalities [21, 22]. All of 
these attributes highlight ferritin and its derivatives as powerful systems with potential application in 
nanomedicine. Indeed, they have been investigated as a novel type of nano-platform for imaging and 
drug delivery in cancer [19, 23]. The aim of this review is to describe recent findings about ferritin 
nanocages’ structure and function, and their biotechnological and biomedical applications for MRI, 
optical imaging and drug delivery in cancer. An overview of strategies used for ferritin surface 
modification to obtain formulations suitable for different clinical uses will be also provided. 
2. Ferritin nanocages: structure and physiological role  
Ferritin is probably the most studied protein after hemoglobin. It has been investigated since 1937, when 
Laufberger described its purification with Cadmium salts [24], and over the last decade it has attracted 
the interest of many nanotechnologists due to its properties [25]. It is a ubiquitous protein found in 
eubacteria, archea, plants and animals, but not in yeast [25]. Ferritin exists in extracellular and 
intracellular compartments, such as the cytosol, nucleus and mitochondria and its main roles are iron 
storage and homeostasis [26]. Therefore, it is one of the most highly conserved molecules.  
Ferritin is a large protein of 450 kDa composed of 24 subunits that self-assemble into a spherical cage-
like structure with inner and outer dimensions of 8 and 12 nm, respectively. Eukaryotes have two ferritin 
genes encoding the heavy (H; 21 kDa) and the light (L; 19 kDa) chains. The H-chain is responsible for 
the oxidation of Fe(II) to Fe(III) and includes the ferroxidase catalytic site, while the L-chain plays a role 
in iron nucleation [27]. H and L chains co-assemble into a 24-mer heteropolymer, where the H-chain to 
L-chain ratio varies according to a tissue specific distribution [25]. Ferritin protects cells from the 
damage caused by the Fenton reaction during oxidative stress, by sequestering Fe
2+
, a source of toxic 
reactive oxygen species, and converting it into harmless Fe
3+
, which is stored as ferrihydrite crystals. 
The ferritin protein cage can accommodate up to 4500 iron atoms [25]. This protective action is crucial 
in the nucleus, where the DNA has to be particularly preserved from iron-induced oxidative damage 
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[28]. Ferritin translocates into the nucleus through an ATP-dependent mechanism [28, 29], and O-
glycosylation of the H-chain seems to be involved in its nuclear translocation, but a Nuclear 
Localization Sequence (NLS) is not required [29]. However, it was not clear whether the integrity of 
ferritin was maintained during translocation. Recently, the Knez group has shed light on this issue by 
demonstrating that ferritin nanoparticles are intact during translocation [30]. 
The ferritin quaternary structure has eight hydrophilic channels that seem to mediate iron transit in and 
out of the protein cage. There are also six hydrophobic channels, which do not seem to be involved in 
iron exchange although they could mediate the transit of protons [31]. In spite of the structural rigidity 
of ferritins in the physiological environment, the protein cages can be reversibly disassembled when the 
pH becomes extremely acidic (pH 2-3) or basic (pH 10-12) [27, 32].  When the pH returns to neutrality 
ferritin monomers are able to self-assemble in a shape memory fashion. Moreover, the ferritin cage is 
resistant to denaturants, including heating to high temperatures (>80 °C) [25].  
Ferritin features have been extensively studied and implemented by researchers, thus allowing the use of 
ferritin nanocages as biological nanoparticles for nanomedical applications.  
 
3. Surface modification of ferritin nanoparticles and cellular interactions 
Extracellular ferritin interacts with cells through the receptor of transferrin 1 (TfR1), which was 
identified in 2010 by Seaman’s group [33]. They demonstrated that TfR1 specifically binds H-ferritin, 
while L-ferritin shows low interaction. After binding on the cell surface, the H-ferritin-TfR1 complex 
is internalized, and can be found in early and recycling endosomes [33, 27], demonstrating that TfR1 
coordinates the processing and the use of iron by binding both Transferrin and H-ferritin [34]. H-
ferritin is also able to interact with the T-cell Immunoglobulin and Mucin domain-2 (TIM-2) [35, 36], 
which is overexpressed in oligodendrocytes and B-cells [37, 38], and is internalized in endosomes 
upon binding [39]. Otherwise, L-ferritin binds to the Scavenger Receptor Class A, Member 5 
(SCARA-5) [40], which is found in macrophages and the retina. Both H and L ferritin nanoparticles 
have been produced via DNA-recombinant technology. H-ferritin, which naturally interacts with the 
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TfR1, are the most extensively studied [33]. By exploiting the TfR1 overexpression in many types of 
tumor cells, Fan and coworkers have developed a ferritin-based system for specifically visualizing 
tumors among normal cells and healthy tissues [41]. That study demonstrated that the intrinsic 
targeting of ferritin towards cancer cells could be used to design naturally targeted nanoparticles for 
theranostic purposes. 
Despite the natural targeting of ferritin towards cancer cells, several research groups have modified the 
surface of ferritin nanocages by inserting a number of target motifs, such as antibodies, peptides and 
antibody fragments, in order to drive nanoparticles towards specific cells by selective recognition 
(Figure 1). Both lysines and cysteines on the ferritin surface have been exploited for chemical 
conjugation using different heterobifunctional cross-linkers with N-hydroxysuccinimide (NHS) ester 
and maleimide groups [42-44]. Lys and Cys residues have also been employed to chemically attach 
dyes, quencher molecules or polyethylene glycol (PEG) molecules [22, 45]. Most conjugation 
strategies have been designed and realized by genetically engineering ferritin monomers. Targeting 
moieties, such as the RGD peptide [46, 47], the anti-melanocyte stimulating hormone peptide [48, 45] 
or the extracellular domain of myelin oligodendrocyte glycoprotein (MOG) [49] have been expressed 
as N-terminal fusion proteins, allowing 24 targeting domains to be exposed on the ferritin cage 
surface, with uniform and precise orientation. In the last year, the surface conjugation of ferritin 
nanoparticles with a composite of four different peptides was reported. That was undertaken by N-
terminal cloning four peptides onto the ferritin sequence: an enzymatically cleaved peptide (ECP) to 
release siRNA, a cationic peptide (CAP) to capture siRNA, a cell penetrating peptide (CPP) and a 
tumor cell targeting (CTP) moiety [50]. N-terminal fusion proteins have also been produced to display 
viral hemagglutinin on the ferritin surface, with the resulting neutralization of H1N1 viruses [51]. 
Alternatively, the production of ferritin nanoparticles with peptides fused at the C-terminal has been 
reported for the development of dendritic cell-based vaccines [52]. Beyond these strategies, other 
approaches for the conjugation of targeting moieties on ferritin surface have also been explored, 
including ferritin nanocage biotinylation in order to insert targeting functionalities [53], or the genetic 
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engineering of ferritin for generating a fusion protein, which exploits N-terminal protein G for 
antibody immobilization [54]. 
 
4. Nanotechnological applications of ferritin  
Ferritin has attracted much interest due to its potential use as reaction chamber for the production of 
metal nanoparticles, or as a template for semi-conductor production [55]. Ferritin nanocages allow 
chemical synthesis to occur in restricted cavities with homogenous shape and atomic composition 
[56]. Ferritin nanocages have been extensively exploited for the biomineralization of metal oxides, 
such as iron [57], manganese [58], cobalt [59], chromium and nickel oxides [60]. Among the different 
protocols, the simplest and most suitable method of mass-production is the one-pot synthesis strategy 
developed by the Yamashita group [56], which developed metal-loaded ferritin nanocages with 
potential for nanoelectronical application [56].  
Nanoparticles obtained from mineralization of semiconductors are very attractive from the 
nanotechnological point of view, since their fluorescence properties are closely related to nanoparticle 
size and shape [56]. In this context, ferritin nanocage cavities have been used for the synthesis of 
semi-conductor nanoparticles. However, the main drawback of this process is that ion aggregation is 
induced by high concentrations of Cd
2+
 or Zn
2+
 and Se
2-
 during the chemical reaction [56, 61], and 
because of this only a few research groups are engaged in its development [56, 61]. The synthesis of 
CdSe and ZnSe using ferritins as a reaction chamber has been successfully obtained by Yamashita and 
coworkers, who have designed a new chemical approach called the Slow Chemical Reaction System 
[62, 63]. This method avoids ion aggregation since Cd
2+
 or Zn
2+
 are attracted inside the apoferritin 
chamber by inner negative residues, thus preventing the aggregation process; therefore, mineralization 
inside an apoferritin cavity slows down the nucleation of CdSe or ZnSe [62-65].  
5. Potential of ferritin nanoparticles in cancer 
While ferritin nanoparticles have been widely investigated in the context of nanotechnology, their 
main application concerns the field of nanomedicine. Indeed, apart from their application in the 
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development of vaccines [51, 52], several research groups are engaged in the study of ferritin as 
imaging and drug delivery systems for the diagnosis and treatment of tumors, as summarized in Table 
1. 
 
5.1 Ferritin nanoparticles as a drug delivery platform 
Their high stability, biocompatibility, ability to disassemble and reassemble in a shape memory 
fashion and disposition for surface modification make ferritin nanoparticles an ideal platform for drug 
delivery [55]. Indeed, in physiological conditions ferritin has a stable 24-mer cage architecture, while 
in highly acidic and basic conditions its quaternary structure disassembles, and then reassembles when 
the pH of the solution is brought to neutrality [66]. This feature has been used to encapsulate 
molecules in solution within ferritin cavities, simply by disassembling and reassembling the 24-mer 
architecture (Figure 2). Drugs with a natural tendency to bind metals, such as cisplatin and 
desferoxamine B [67], have been easily entrapped in the ferritin shell. Cisplatin encapsulation was 
first reported in 2007 by Gao and coworkers [68], who also studied the cellular uptake of these 
nanoparticles and several applications in tumor treatment [69]. The Huang group has used cisplatin-
loaded apoferritin to study, with a proteomic approach, the apoptotic process induced by nanoparticles 
in gastric cancer cells [70]. Moreover, a drug delivery device targeted to melanomas has been 
developed using cisplatin-loaded ferritin, chemically functionalized with an antibody against the 
melanoma antigen CSPG4 [42]. These studies have provided strong evidence of an enhanced efficacy 
of antiblastic therapy when it is encapsulated in ferritin-based nanoparticles, particularly in terms of 
targeting cancer cells such as melanoma, a type of cancer totally refractory to chemotherapy in later 
stages [42]. 
However, most of the currently used chemotherapies are not based on metals such as cisplatin, and the 
incorporation of non-metal-containing drugs within ferritin is complicated by their limited interaction 
with the protein cage. To overcome this drawback, different approaches have been evaluated, mainly 
focused on forming complexes of drugs with transition metals or the addition of charged accessory 
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molecules [3, 71]. Doxorubicin (DOX) encapsulation in ferritin nanocages represents the most 
extensively investigated system for delivery of anticancer drugs [47]. DOX is a widely used cytotoxic 
drug for several types of solid tumors and has an excellent anticancer activity; however, its use is 
dose-limiting since it is associated with several major toxicities, when administered at high doses [47]. 
DOX pre-complexed with Cu(II) has been loaded inside ferritin nanocages and evaluated in vitro and 
in vivo in U87MG glioblastoma tumor models. Eighty percent of DOX was gradually released from 
RGD-functionalized apoferritin within 10 hours of incubation at 37 °C in phosphate buffered saline 
(PBS), while the copper remained bound to the internal surfaces of the nanocages. This targeted 
nanoformulation has increased drug tumor uptake and accumulation, tumor growth inhibition, 
circulation half-life, and has reduced the cardiotoxicity induced by free DOX [47]. Other groups have 
set up DOX loading strategies that do not involve complexes with transition metals. In these cases, 
good encapsulation efficiency has also been obtained [72, 73, 27], and excellent results in terms of 
tumor growth inhibition and reduced toxicity have been reported, both in vitro [27] and in vivo [73]. 
In vivo results clearly demonstrated that ferritin nanocages improve DOX bioavailability, tumor 
accumulation and clearance, and suggested that ferritin-mediated active targeting provides a major 
contribution (Figure 4) [73]. The mechanisms and kinetics of drug release from ferritin shell has not 
been completely elucidated, although reported data with DOX suggest that encapsulation is stable in 
serum and that a pH-triggered release takes place in vitro [75]. Moreover, the Knez group 
demonstrated that ferritin translocates into the nucleus mediating the nuclear release of DOX, while 
our group has hypothesized that DOX loaded ferritin acts as a Trojan horse because it has been 
translocated into the nucleus following DNA damage caused by the partial release in the cytoplasm of 
encapsulated DOX, by a self-triggered translocation mechanism which releases the drug directly into 
the nuclear compartment [27, 30]. 
In this context, the use of unfunctionalized ferritin seems to be advantageous for many reasons: 1) 
higher purification yield [72, 27]; 2) high tumor recognition [72] specific tumor recognition mediated 
by TfR1; 3) ferritin specific physiological behavior is not prevented, allowing the nuclear 
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translocation for the release of DOX to be exploited [27]. Furthermore, ferritin nanoparticles have 
been used to stabilize lipophilic drugs, such as curcumin [74]. However, to date few studies have been 
published on this, probably because low drug hydro solubility strongly affects the encapsulation 
reaction.  
Ferritin-based nanocages could be implemented for the delivery of radioisotopes increasing loading 
efficiency and improving pharmacokinetics. Hainfeld has developed ferritin cages with a payload of 
about 800 
235
U atoms/nanoparticle, able to kill surrounding tumor cells [75]. The same strategy has 
been suggested as being applicable with other isotopes currently used in clinics, such as 
90
yttrium and 
177
luthetium [3].  
Finally, ferritin nanocages have been employed for siRNA or miRNA delivery. These short non-
coding RNA molecules, have been strongly related to either cancer progression or resistance, 
suggesting that miRNA/siRNA-based therapy could be associated with standard treatment. Lee and 
coworkers have recently proposed a genetic variant of H-ferritin designed to mediate targeted delivery 
and internalization of siRNA immobilized on the nanoparticle surfaces through charge-charge 
interaction [50]. In vitro results demonstrated the efficacy of the as-designed nanoparticle in targeting 
tumor cells and the nanoparticle-mediated intracellular delivery of an anti-red fluorescent protein 
(RFP) siRNA, which induced RFP suppression [50]. This result paves the way for future application 
of ferritin nanoparticles in gene silencing.  
 
5.2 Ferritin nanoparticles for in vivo imaging 
The plasticity of ferritin as a mineralization chamber for heavy atoms or complexes, and the 
possibility of modifying ferritin nanocages by protein engineering or by chemical reaction to insert 
probe molecules, are features that make ferritin an ideal device for imaging [53]. In particular, ferritins 
have found great application in magnetic resonance imaging (MRI) and optical [73] imaging (Figure 
3). Indeed, MRI is a powerful diagnostic technique with wide involvement in tumor imaging, thanks 
to its high sensitivity and accuracy [55]. However, the currently used gadolinium-based contrast 
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agents indistinctly enhance all highly vascularized tissues, and thus lack specificity for cancer cells 
resulting in a high rate of false positives. On the other hand, occult cancer micro-deposits may be not 
detected on MRI due to an insufficient spatial resolution, and oligometastatic disease could be 
misdiagnosed [76, 77]. Both endogenous and exogenous ferritins have demonstrated great utility in 
this area by overcoming these limitations. Ferritin nanoparticles loaded with magnetic species have 
been developed as MRI contrast agents for tumor imaging. Cao and coworkers have obtained a 
nanoparticle with transverse relaxivity r2 of 224 mM
-1
 s
-1
, by synthesizing a single crystal of magnetite 
inside the ferritin cage [78]. Injection of such nanoparticles in MDA-231 tumor-bearing mice caused a 
drop of the T2 signal due to TfR1-dependent tumor accumulation [78]. Moreover, iron nanoparticles 
have been produced into ferritin cages, and optimizing strategies have been developed by Uchida et al. 
by simply adjusting the extent of Fe loading [79]. The increased amount of iron in the reaction 
mixture determines an increase in the core size of iron nanoparticles encapsulated into ferritin, which 
is directly related to T2 contrast power [79, 80]. Other types of MRI-detectable nanoparticles have 
been produced using the ferritin cavity as a reaction chamber. Five nm Gd nanoparticles have been 
produced inside ferritins, obtaining nanoparticles with longitudinal and transverse relaxivity from 10 
to 70 times higher than commercially available Gd-chelates [81]. Mn-coupled ferritin-based MRI 
contrast agent, obtained by reduction of β-MnOOH, has been reported by Kalman and coworkers. This 
nanoparticle contains up to 300-400 Mn(II) ions and an r1 relaxivity ranging between 4000-7000 s
-1
 
[82]. Aime et al. exploited a pH-mediated ferritin disassembly to load about 8-10 Gd-
HPDO3A/nanoparticle, obtaining a r1 relaxivity of 80 mM
-1
 s
-1
 [83]. Upon modification with C3d, a 
peptide that specifically recognizes vessel endothelium, Gd-nanoparticles showed a 30% signal 
increase in tumor in a mouse model [53]. 
Ferritin nanoparticles can also be conjugated with dye molecules and find application as optical 
imaging probes in imaging-guided surgery for cancer [84]. Li et al. employed a ferritin H-chain 
genetically fused with epidermal growth factor (EGF), and subsequently labeled Cys residues with 
Alexa Fluor 750, for targeting EGFR-overexpressing breast cancer cells in mice [85]. Besides, Lin et 
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al. developed a Cy5.5-labelled ferritin by reacting the dye with the protein’s primary amine. Then, 
using the pH-disassembly procedure, the Cy5.5-labelled ferritin monomers were mixed with RGD-
bearing ferritin monomers. The resulting hybrid ferritin, which displays on the surface both the Cy5.5 
dye and the RGD peptide, has been injected into U87MG tumor-bearing mice demonstrating good 
tumor accumulation [22]. In another study, Lin and coworkers mixed monomers of ferritin conjugated 
with the Cy5.5-GPLGVRG peptide or with the black hole quencher-3 (BHQ-3), obtaining a hybrid 
nanoparticle that emits fluorescence only in a metalloproteinase rich environment, such as that found 
in tumors [43]. This nanoparticle was further implemented through the encapsulation of 
64
Cu, a 
radioisotope commonly used in positron emission tomography (PET), thus obtaining a ferritin 
platform for multimodal imaging (Figure 5) [22]. Combining optical and nanotargeted strategies could 
improve and refine intraoperative imaging, to properly excise a tumor lesion with adequate margins, 
and provide targeted diagnostic tools for cancer follow up. 
 
5.3 Ferritin nanoparticles in photothermal therapy 
Thanks to its high biocompatibility, low immunogenicity and good pharmacokinetics profile ferritin is 
useful in photothermal therapy (PTT) [86]. PTT employs photothermal agents, which absorb the 
irradiation energy of an optical laser and convert it into heat for killing cancer cells. Indeed, most of 
the photothermal agents show high immunogenicity, non-biodegradability, long term toxicity and poor 
pharmacokinetics, which strongly affect their clinical application [87, 88]. Haung et al. have reported 
the development of a near infra-red (NIR)-loaded ferritin, which displayed strong absorbance in the 
NIR region for photoacustic/fluorescence multimodal imaging-guided PTT [89, 90]. The as-designed 
ferritin nanovector exhibited in vivo high PTT efficacy and low systemic toxicity in comparison to the 
free dye [90]. Another kind of ferritin nanoparticle has been developed by the Ceci group as a 
platform for hyperthermia. They functionalized the ferritin cage with the melanoma targeting peptide 
and used it as a mineralization chamber for the synthesis of cobalt-doped ferrite nanoparticles. The as-
synthesized nanoparticles were uniform in size (6-7 nm) and morphology (spherical). Moreover, they 
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displayed an in vitro hyperthermic efficacy inversely related to the amount of Co used for the doping 
[45]. Altogether, the reported data suggest that ferritin nanocages could be a promising vector for 
photothermal therapy, although further studies have to be performed to better investigate ferritin’s 
potential in this field. 
 
6. Conclusions and future perspectives 
So far, nanotechnology has emerged as promising frontier in cancer treatment. Super-paramagnetic 
iron oxide nanoparticles (SPIONs) are being tested in clinical trials as magnetic contrast agents for 
MRI and for intraoperative sentinel node identification during breast cancer surgery [91, 92]. 
Liposomes have been already established in clinical practice for improving bioavailability and 
reducing toxicity profile of some excellent cytotoxic drugs associated with severe cardiotoxicity, such 
as anthracyclines [93]. Nanoformulated albumin-bound paclitaxel has been notoriously introduced in 
clinical management of various types of cancer with encouraging results in terms of anticancer 
efficacy [94]. However, these basic nanoparticles lack a specific method of cancer targeting, and 
despite their benefit in reducing side effects of cytotoxic drugs in clinical trials, no substantial 
improvement in long-term outcomes has been documented [95]. In this context, ferritin nanocages 
appear to be powerful and fascinating tools for both imaging and therapeutic purposes, in particular 
considering that ferritin is a protein normally present in physiological systems. 
Different strategies of loading ferritin with drugs, molecules and metals have been successfully 
explored; nevertheless, some aspects particularly regarding their kinetic release from the nanovector 
still need to be investigated in detail. Much work has already been done to increase the types of 
molecules encapsulated, particularly in the case of non-metal-containing drugs, which include the 
majority of chemotherapeutics. However, a few questions remain: (1) the fate of ferritin and its 
derivatives after systemic injection and (2) the possibility to suppress ferritin uptake in off-target 
organs and/or sequestration by the reticulo-endothelial system, and thereby (3) the hope to extend a 
drug’s half-life by modifying the ferritin surface with stealth moieties. Some research groups have 
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taken advantage of the ability of H-ferritin to specifically recognize TfR1 [33], a receptor expressed 
on the surface of many types of cancer cells [41]. Other groups have chemically or genetically inserted 
targeting motifs onto the ferritin surface, to improve tumor homing [42-54]. This strategy has been 
demonstrated to be very promising, since targeted therapies are probably the key for cancer treatment 
[96]. Specific targeting of cancer cell receptors enhances anticancer activity by selective inhibition of 
the underlying cellular pathways, and mediates a selective release of cytotoxic drugs. However, 
despite the fact that surface modification of ferritin imparts target specificity, it is not clear whether or 
not these modifications alter the nanoparticle’s immunogenicity. Another aspect which should not be 
underestimated is the possibility of combination therapy. Encapsulation of various drugs into the same 
nanocage would provide contemporary multiple anticancer activities towards various cancer survival 
pathways. Finally, the intrinsic capability of ferritin nanocages to undergo nuclear translocation can be 
exploited to design a novel class of smart nanodrugs, which could act as “Trojan horses”, by releasing 
chemotherapy into the nucleus of cancer cells, thus strongly improving their cytotoxic activity. At 
present, unfunctionalized DOX-loaded ferritin represents the most extensively investigated of the 
ferritin-based nanoparticles, and several in vitro and in vivo studies have demonstrated it to be 
successful. However, such nanoparticles are currently not used in clinical practice, and further 
research is required before clinical translation. Ferritin has also found an intriguing application in the 
field of in vivo imaging. Particularly, ferritin-based contrast agents for MRI have been developed, 
providing an imaging platform with increased tumor accumulation in comparison to the contrast 
agents currently used in clinical practice. However, toxicity, biodistribution and clearance of these 
nanocompounds needs to be more clearly understood before their clinical translation. Overall, ferritin 
nanocages are promising nano-platforms for imaging and therapy of cancer. Some issues still need to 
be thoroughly investigated, but many significant results have already been obtained. Physiological 
features and the bioengineering versatility of ferritin-based nanocages make their translation from 
bench to bedside a reasonable possibility. Moreover, the combination of imaging and therapeutic 
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functionality into ferritin nanocages seems to be the most promising and fascinating frontier  in cancer 
theranostics.  
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FIGURES AND TABLES 
 
 
Figure 1. Schematic representation of strategies adopted to provide surface functionalization of ferritin 
with targeting peptides, antibodies, siRNA and fluorescent dyes. 
Table 1. Main application prospects of ferritin nanocages in cancer diagnosis and treatment. 
Loaded with… Functionalized with… Application Ref. number 
Cisplatin - Chemotherapy 68, 69, 70 
Cisplatin antibody against the 
melanoma antigen CSPG4 
Chemotherapy 42 
Doxorubicin RGD peptide Chemotherapy 47 
Doxorubicin - Chemotherapy 27, 72, 73, 75, 30 
Curcumin - Therapy 74 
235
U - Radionuclide Therapy 75 
- anti-red fluorescent protein 
(RFP)  siRNA 
RNA interference Therapy 50 
Magnetite crystal  MR Imaging 78, 79, 80 
Gadolinium  MR Imaging 81, 83 
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Mn(II)  MR Imaging 82 
Gadolinium C3d MR Imaging 53 
- EGF 
Alexa Fluor 750 
Fluorescence Imaging 85 
- RGD peptide 
Cy5.5 
Fluorescence Imaging 22 
- Cy5.5 
GPLGVRG peptide  
black hole quencher-3 
(BHQ-3) 
Fluorescence Imaging  
64
Cu RGD peptide 
Cy5.5 
Positron Emission Tomography 22 
NIR - Photothermal Therapy 90, 91 
Cobalt-doped ferrite 
nanoparticles 
Melanoma targeting peptide 
(MSH) 
Magnetic Fluid Hyperthermia 45 
 
 
Figure 2. Schematic representation of ferritin developed for drug delivery to cancer. 
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Figure 3. Schematic representation of ferritin developed for cancer imaging. 
 
Figure 4. Schematic representation of in vivo drug delivery of ferritin nanoparticles. 
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Figure 5. In vivo imaging with ferritin nanoparticles. In vivo images of (a) positron emission 
tomography (PET) and (b) near-infrared fluorescence images after administration of ferritin nanocages. 
30 min before ferritin probe administration, mice were injected with a blocking dose of c(RGDyK) to 
demonstrate target specificity. (Reprinted with permission from Ref 22. Copyright 2011 American 
Chemical Society). 
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